Acurx Pharmaceuticals
NASDAQ: ACXPStaten Island, US · Founded 2017 · Delaware corporation
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting bacterial infections classified as priority pathogens by the WHO, CDC, and FDA. It is a publicly held company focused on antibiotic drug development.
Founders & leadership
Acurx Pharmaceuticals was founded in 2017 by Robert J. DeLuccia, David P. Luci, and David Luci.
RJ
Robert J. DeLucciaCo-founder
DP
David P. LuciCo-founder
DL
David LuciinFounder
RG
Robert G. ShawahExecutive
Board
JS
Joseph ScodariBoard director
CS
Carl SailerBoard director
JD
James DonohueBoard director
JH
Jack H. DeanBoard director
TH
Thomas HarrisonBoard director
Reported raises · per SEC filings
Form D private placements$22.6M disclosed across 6 of 7 rounds · 2018–2026
▶$4.6MraisedApr 2026 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.6MraisedApr 2026 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jack H. DeanDirector
- James DonohueDirector
- Thomas HarrisonDirector
- Robert J. DeLucciaExecutive Officer, Director
- Joseph ScodariDirector
- Carl SailerDirector
- Robert G. ShawahExecutive Officer
- David P. LuciExecutive Officer, Director
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJun 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedJun 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT G. SHAWAHExecutive Officer
- JAMES DONOHUEDirector
- CARL SAILERDirector
- JOSEPH SCODARIDirector
- ROBERT J. DELUCCIAExecutive Officer, Director
- THOMAS HARRISONDirector
- JACK H. DEANDirector
- DAVID P. LUCIExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- Sales commissions
- $186.7K
- Placement agents
- H.C. WAINWRIGHT & CO., LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12MofferedMay 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$12MofferedMay 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jack H. DeanDirector
- David P. LuciExecutive Officer
- James DonohueDirector
- Joseph ScodariDirector
- Thomas HarrisonDirector
- Robert J. DeLucciaExecutive Officer, Director
- Robert G. ShawahExecutive Officer
- Carl SailerDirector
- Offering amount
- $12M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.4MraisedMar 2025 · 6 investors · PharmaceuticalsRule 506(b)
▶$3.4MraisedMar 2025 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. ShawahExecutive Officer
- Jack H. DeanDirector
- Joseph ScodariDirector
- James DonohueDirector
- Carl SailerDirector
- Robert J. DeLucciaExecutive Officer, Director
- Thomas HarrisonDirector
- David P. LuciExecutive Officer
- Offering amount
- $3.4M
- Amount sold
- $3.4M
- Sales commissions
- $117.8K
- Finders' fees
- $117.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedJan 2025 · 12 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedJan 2025 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Joseph ScodariDirector
- Carl SailerDirector
- James DonohueDirector
- Robert G. ShawahExecutive Officer
- Robert J. DeLucciaExecutive Officer, Director
- Jack H. DeanDirector
- Thomas HarrisonDirector
- David P. LuciExecutive Officer
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Sales commissions
- $163.1K
- Finders' fees
- $110K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$455KraisedJan 2020 · 21 investors · BiotechnologyRule 506(b)
▶$455KraisedJan 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert G. ShawahExecutive Officer
- Carl SailerDirector
- Anthony JadhonDirector
- Paul BaehrDirector
- Mark RathjenDirector
- David P. LuciExecutive Officer, Director
- Robert J. DeLucciaExecutive Officer, Director
- Michael DuffyDirector
- John TerranaDirector
- Katie JadhonDirector
- Offering amount
- $6M
- Amount sold
- $455K
- First sale
- Jan 2020
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
▶$7.8MraisedOct 2019 · 202 investors · BiotechnologyRule 506(b)
▶$7.8MraisedOct 2019 · 202 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David P. LuciDirector
- Robert J. DeLucciaDirector
- Robert G. ShawahExecutive Officer
- Offering amount
- $7.8M
- Amount sold
- $7.8M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView22 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Acurx Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Acurx Pharmaceuticals do?
- Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new class of antibiotics targeting bacterial infections classified as priority pathogens by the WHO, CDC, and FDA. It is a publicly held company focused on antibiotic drug development.
- Who founded Acurx Pharmaceuticals?
- Acurx Pharmaceuticals was founded by Robert J. DeLuccia, David P. Luci, David Luci in 2017.
- How much funding has Acurx Pharmaceuticals raised?
- Acurx Pharmaceuticals has disclosed $22.6M raised across 6 of its 7 known rounds.
- Where is Acurx Pharmaceuticals headquartered?
- Acurx Pharmaceuticals is headquartered in Staten Island, US.